Pioneering treatment.

LONDON (AFP) repots that there was approval pioneering treatment for brain cancer for commercial use in Switzerland. "We are delighted to be the first company to reach the market with a personalized therapeutic vaccine for brain cancers, which carry a very bleak prognosis for patients," said Alton Boynton, president and chief executive of Northwest Biotherapeutics. DCVax-Brain is designed to treat cancer by priming the patient's immune system to attack cancer cells. The Swiss Agency for Therapeutic Products, known as Swissmedic, decided to approve the company's request for a commercial licence on the basis of ongoing clinical data, Northwest Biotherapeutics said.
One wants to be in hope for the first step will be successful.